Literature DB >> 2847772

Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives.

M Johnson1, T Caiazzo, J M Molina, R Donahue, J Groopman.   

Abstract

We have studied the in vitro effects of nucleoside inhibitors of reverse transcriptase on bone marrow myeloid and erythroid progenitor development. Both 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC) potently inhibited in vitro haematopoiesis, while 2',3'-dideoxyadenosine (DDA) was less inhibitory in this culture system. Studies of candidate antiretroviral agents in bone marrow culture may predict clinical toxicity as well as lead to strategies for combination therapy which minimize impairment of haematopoiesis.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2847772     DOI： 10.1111/j.1365-2141.1988.tb02454.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  12 in total

1.  Inhibition of immune functions by antiviral drugs.

Authors:  W Heagy; C Crumpacker; P A Lopez; R W Finberg
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 2.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy.

Authors:  L E Mathes; K A Hayes; G Kociba
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  A cellular model for drug interactions on hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis.

Authors:  M C Léglise; P Darodes de Tailly; J L Vignot; M A Le Bot; A M Le Roux; C Riché
Journal:  Cell Biol Toxicol       Date:  1996-02       Impact factor: 6.691

5.  In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors.

Authors:  S Hayashi; R L Fine; T C Chou; M J Currens; S Broder; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

6.  In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model.

Authors:  P J Polas; C L Swenson; R Sams; C M Cheney; K A Hayes; M J Tarr; G J Kociba; L E Mathes
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

7.  In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans.

Authors:  R E Dornsife; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 8.  Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).

Authors:  R Whittington; R N Brogden
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 9.  Didanosine, a new antiretroviral drug. A review.

Authors:  R M Franssen; P L Meenhorst; C H Koks; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

10.  Granulocyte colony-stimulating factor treatment in AIDS patients.

Authors:  U R Hengge; N H Brockmeyer; M Goos
Journal:  Clin Investig       Date:  1992-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.